UMIN ID: UMIN000044475
Registered date:20/06/2021
An Observational Study of Japanese Participants With X-linked Retinitis Pigmentosa
Basic Information
Recruitment status | Complete: follow-up complete |
---|---|
Health condition(s) or Problem(s) studied | X-Linked Retinitis Pigmentosa |
Date of first enrollment | 2021/07/30 |
Target sample size | 15 |
Countries of recruitment | Japan |
Study type | Observational |
Intervention(s) |
Outcome(s)
Primary Outcome | Visual Function Up to Day 30 Visual function will be assessed using visual acuity. Retinal Structure Up to Day 30 Retinal structure will be assessed using spectral domain optical coherence tomography (SDOCT). Retinal Function Up to Day 30 Retinal function will be assessed using static visual field testing. |
---|---|
Secondary Outcome |
Key inclusion & exclusion criteria
Age minimum | 5years-old |
---|---|
Age maximum | Not applicable |
Gender | Male and Female |
Include criteria | |
Exclude criteria | - Are unable or unwilling to undertake consent or clinical testing - Participated in another research study and had intraocular surgery within 3 months of screening - Significant ophthalmologic diseases |
Related Information
Primary Sponsor | Janssen Pharmaceutical K.K. |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | Janssen Pharmaceutical K.K. |
Secondary ID(s) |
Contact
public contact | |
Name | Personnel Medical Information Center |
Address | 3-5-2 Nishikanda, Chiyoda-ku, Tokyo, Japan Japan 101-0065 |
Telephone | 0120-183-275 |
DL-JANJP-JCO_TL_TSG_EMP@its.jnj.com | |
Affiliation | Janssen Pharmaceutical K.K. Medical Information Center |
scientific contact | |
Name | Hirotaka Numaguchi |
Address | 3-5-2 Nishikanda, Chiyoda-ku, Tokyo, Japan Japan |
Telephone | 0120-183-275 |
DL-JANJP-JCO_TL_TSG_EMP@its.jnj.com | |
Affiliation | Janssen Pharmaceutical K.K. R&D Div. Clinical Science Div. Clinical Development Dept. Medical Group |